China's LBO market to survive Harbin, Xugong setbacks

31 Mar 2006

The group of private equity investors buying into Harbin Pharmaceutical Group, China's largest drug manufacturer, has cancelled the acquisition loan, it emerged this week. Meanwhile, the other Chinese LBO in the market at the moment, the Carlyle Group's purchase of state-owned Xugong Group Construction Machinery, is still languishing ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.

Oops, something went wrong

We're sorry but at the moment we can't load this data